Interim results from an ongoing clinical study presented at the 2025 American College of Veterinary Internal Medicine (ACVIM) Forum in Louisville, Ky., suggest that combining immunotherapy with chemotherapy may improve outcomes in dogs with osteosarcoma, a highly aggressive bone cancer. The oral abstract presentation, "Adoptive Cell Therapy with Chemotherapy Improves Canine Osteosarcoma Outcomes Compared to Standard of Care Chemotherapy," was presented by Jeffrey N. Bryan, DVM, MS, PhD, DACVIM(O), professor of Oncology and associate director of the Ellis Fischel Cancer Center at the University of Missouri. The research compared 14 dogs treated with one dose of carboplatin followed by ELIAS Cancer Immunotherapy (ECI) to 14 matched control dogs receiving the current standard of care—four doses of carboplatin. The combined treatment group showed a one-year survival rate of 71 percent, significantly higher than the 21 percent observed in the control group. The approach appeared well-tolerated and may represent a promising direction in canine cancer treatment.
